ARA-290

Overview

ARA 290, also known as cibinetide, is an investigational peptide derived from the structure of erythropoietin (EPO). Unlike EPO, however, it is specifically designed to be non-erythropoietic, meaning it does not stimulate red blood cell production. This separation is deliberate: researchers sought to capture EPO's tissue-protective and anti-inflammatory properties while avoiding the blood-thickening effects that limit EPO's broader use.

The peptide works through what has been called the innate repair receptor, a signaling complex distinct from the classical EPO receptor on red blood cell precursors. By targeting this pathway, ARA 290 is being explored as a way to reduce inflammation and support tissue repair, particularly in nerves. Its leading research interest has been in conditions involving small-fiber neuropathy and chronic neuropathic pain.

ARA 290 is an investigational compound. It has been the subject of clinical research, most notably in sarcoidosis-associated small-fiber neuropathy, but it is not an approved medication. Its development sits at the intersection of pain management and regenerative medicine. While the underlying concept is biologically interesting, it remains experimental, and its place in clinical practice has not yet been established.

How it works

ARA 290 is built around a specific region of the erythropoietin molecule that is responsible for tissue protection rather than red blood cell stimulation. Erythropoietin has two distinct activities: a hematopoietic effect mediated by the classical EPO receptor, and a separate cytoprotective effect. ARA 290 was engineered to selectively engage the latter, signaling through the innate repair receptor, a heteromeric complex involving the EPO receptor subunit paired with the beta common receptor.

Activation of this receptor is associated with anti-inflammatory and tissue-protective responses. In the context of nerve injury and neuropathy, this is thought to dampen harmful inflammatory signaling and support the survival and function of small nerve fibers. Because the peptide does not appreciably activate the classical pathway that drives red blood cell production, it is intended to avoid the increased clotting risk and elevated blood viscosity that accompany EPO therapy.

This targeted approach is the core scientific rationale behind ARA 290. By decoupling tissue protection from blood cell stimulation, the peptide aims to deliver therapeutic benefit with a more favorable safety profile. Whether this elegant mechanism reliably translates into meaningful clinical outcomes in patients is the central question that ongoing and prior research has sought to address.

Research & evidence

ARA 290 has progressed further into human research than many experimental peptides, having been studied in clinical trials. The most prominent investigations have focused on small-fiber neuropathy associated with sarcoidosis, a condition in which damaged small nerve fibers cause chronic pain and autonomic symptoms. In these studies, researchers examined whether the peptide could reduce neuropathic pain and improve measures of nerve function and quality of life.

Reported results have included signals of benefit, such as improvements in patient-reported pain and certain measures related to nerve fiber health. These findings have been encouraging enough to sustain continued interest in the compound for neuropathic conditions. Work has also explored its potential in other contexts involving inflammation and tissue injury, reflecting the broad biological role of the pathway it targets.

Nevertheless, the overall evidence base remains limited in size and scope. The trials conducted to date are relatively small, and the compound has not completed the large, confirmatory studies that would be required for regulatory approval. As with many investigational agents, early positive signals must be interpreted cautiously until replicated in larger populations. ARA 290 is a promising but still unproven therapy whose ultimate clinical value is not yet determined.

Safety & legal status

A central part of ARA 290's design rationale is safety: by avoiding stimulation of red blood cell production, it is intended to sidestep the thrombotic and cardiovascular risks linked to erythropoietin. In clinical research it has generally been described as reasonably tolerated, but the safety data come from a limited number of relatively small studies. This means that rare or long-term adverse effects may not yet be fully understood, and conclusions about its safety remain provisional.

Because ARA 290 is investigational, it should be used only within the context of properly supervised clinical research. Material obtained outside of formal medical or trial settings cannot be assumed to be pure, accurately dosed, or safe, which introduces risks unrelated to the peptide's intrinsic properties. This is a particular concern for any peptide that circulates through unregulated channels.

From a legal and regulatory perspective, ARA 290 is not an approved drug. It has not received marketing authorization from the FDA or comparable agencies for neuropathic pain, sarcoidosis, or any other indication. It is not a dietary supplement and is not legally marketed for general consumer use. Its appropriate status today is that of an experimental therapeutic under investigation, not an available treatment.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012. Peer-reviewed study
2. Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013. Peer-reviewed study
3. van Velzen M, Heij L, Niesters M, et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs. 2014. Peer-reviewed study
4. Zhang W, Yu G, Zhang M. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides. 2016. Peer-reviewed study
5. Watanabe M, Lundgren T, Saito Y, et al. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation. 2016. Peer-reviewed study
6. Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015. Peer-reviewed study